By Elizabeth Cheung
Hong Kong patients could benefit from taking part in more clinical trials in mainland China, and vice versa for those on the other side of the border, according to the CEO of a government-owned institute that is exploring the projects and looking to boost biomedical innovation in the Greater Bay Area.
Professor Bernard Cheung Man-yung, CEO of the Greater Bay Area International Clinical Trial Institute, said his organisation would explore initiatives that benefited patients.
鈥淐an a patient from…